Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials
IntroductionInflammatory Bowel Disease (IBD), encompassing Crohn disease (CD) and ulcerative colitis (UC), presents complex challenges in management due to dysregulated immune responses and genetic predispositions. This study explored the potential of curcumin as an adjunctive therapy in IBD, assess...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2025.1494351/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850094726979518464 |
|---|---|
| author | Saeid Mohseni Ali Tavakoli Hamid Ghazipoor Neda Pouralimohamadi Roghayeh Zare Thomas Rampp Maryam Shayesteh Mehdi Pasalar |
| author_facet | Saeid Mohseni Ali Tavakoli Hamid Ghazipoor Neda Pouralimohamadi Roghayeh Zare Thomas Rampp Maryam Shayesteh Mehdi Pasalar |
| author_sort | Saeid Mohseni |
| collection | DOAJ |
| description | IntroductionInflammatory Bowel Disease (IBD), encompassing Crohn disease (CD) and ulcerative colitis (UC), presents complex challenges in management due to dysregulated immune responses and genetic predispositions. This study explored the potential of curcumin as an adjunctive therapy in IBD, assessing its efficacy and safety through a systematic review of clinical trials to enhance treatment strategies and outcomes.MethodsTo identify placebo-controlled randomized clinical trials on curcumin treatment in IBD, databases such as Medline/PubMed, Scopus, Embase, Web of Knowledge, and Google Scholar were searched till May 2024. Inclusion criteria focused on RCTs comparing curcumin with placebo in IBD patients, with data extraction and analysis conducted using established methodologies and tools for comprehensive synthesis and assessment of study findings.ResultsIn this meta-analysis, 13 placebo-controlled RCTs on curcumin treatment in IBD were included after screening 362 records and conducting a full-text review. Most trials focused on UC patients and were published post-2010, utilizing oral curcumin with varying dosages and durations. The analysis showed curcumin’s significant efficacy in achieving clinical remission and response in UC patients, with heterogeneity observed. Adverse events and withdrawal rates did not significantly differ between curcumin and placebo groups. In CD patients, curcumin did not show superiority over placebo for clinical and endoscopic remission.ConclusionThe findings highlight curcumin’s potential as a treatment for UC but indicate inconclusive results for CD, emphasizing the need for further research. The multifaceted mechanisms of curcumin’s efficacy in IBD involve anti-inflammatory, antioxidant, microbiota modulatory, and immune-regulating properties. Further research is warranted to enhance understanding and treatment efficacy.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD42024567247. |
| format | Article |
| id | doaj-art-dd1dd4d2e8b248ea8f55777171df500f |
| institution | DOAJ |
| issn | 2296-861X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj-art-dd1dd4d2e8b248ea8f55777171df500f2025-08-20T02:41:36ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2025-03-011210.3389/fnut.2025.14943511494351Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trialsSaeid Mohseni0Ali Tavakoli1Hamid Ghazipoor2Neda Pouralimohamadi3Roghayeh Zare4Thomas Rampp5Maryam Shayesteh6Mehdi Pasalar7Department of Persian Medicine, School of Persian Medicine, Babol University of Medical Sciences, Babol, IranResearch Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, IranDepartment of Family Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranDepartment of Family Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranDepartment of Persian Medicine, School of Persian Medicine, Shahid Sadoughi University of Medical Sciences, Ardakan, Yazd, IranCenter for Integrative Medicine and Planetary Health, University Hospital Essen, University of Duisburg-Essen, Essen, GermanyDepartment of Traditional Pharmacy and Persian Medicine, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, IranResearch Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, IranIntroductionInflammatory Bowel Disease (IBD), encompassing Crohn disease (CD) and ulcerative colitis (UC), presents complex challenges in management due to dysregulated immune responses and genetic predispositions. This study explored the potential of curcumin as an adjunctive therapy in IBD, assessing its efficacy and safety through a systematic review of clinical trials to enhance treatment strategies and outcomes.MethodsTo identify placebo-controlled randomized clinical trials on curcumin treatment in IBD, databases such as Medline/PubMed, Scopus, Embase, Web of Knowledge, and Google Scholar were searched till May 2024. Inclusion criteria focused on RCTs comparing curcumin with placebo in IBD patients, with data extraction and analysis conducted using established methodologies and tools for comprehensive synthesis and assessment of study findings.ResultsIn this meta-analysis, 13 placebo-controlled RCTs on curcumin treatment in IBD were included after screening 362 records and conducting a full-text review. Most trials focused on UC patients and were published post-2010, utilizing oral curcumin with varying dosages and durations. The analysis showed curcumin’s significant efficacy in achieving clinical remission and response in UC patients, with heterogeneity observed. Adverse events and withdrawal rates did not significantly differ between curcumin and placebo groups. In CD patients, curcumin did not show superiority over placebo for clinical and endoscopic remission.ConclusionThe findings highlight curcumin’s potential as a treatment for UC but indicate inconclusive results for CD, emphasizing the need for further research. The multifaceted mechanisms of curcumin’s efficacy in IBD involve anti-inflammatory, antioxidant, microbiota modulatory, and immune-regulating properties. Further research is warranted to enhance understanding and treatment efficacy.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD42024567247.https://www.frontiersin.org/articles/10.3389/fnut.2025.1494351/fullcurcumininflammatory bowel diseaseCrohn diseaseulcerative colitisintegrative medicineherbal medicine |
| spellingShingle | Saeid Mohseni Ali Tavakoli Hamid Ghazipoor Neda Pouralimohamadi Roghayeh Zare Thomas Rampp Maryam Shayesteh Mehdi Pasalar Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials Frontiers in Nutrition curcumin inflammatory bowel disease Crohn disease ulcerative colitis integrative medicine herbal medicine |
| title | Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials |
| title_full | Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials |
| title_fullStr | Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials |
| title_full_unstemmed | Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials |
| title_short | Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials |
| title_sort | curcumin for the clinical treatment of inflammatory bowel diseases a systematic review and meta analysis of placebo controlled randomized clinical trials |
| topic | curcumin inflammatory bowel disease Crohn disease ulcerative colitis integrative medicine herbal medicine |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2025.1494351/full |
| work_keys_str_mv | AT saeidmohseni curcuminfortheclinicaltreatmentofinflammatoryboweldiseasesasystematicreviewandmetaanalysisofplacebocontrolledrandomizedclinicaltrials AT alitavakoli curcuminfortheclinicaltreatmentofinflammatoryboweldiseasesasystematicreviewandmetaanalysisofplacebocontrolledrandomizedclinicaltrials AT hamidghazipoor curcuminfortheclinicaltreatmentofinflammatoryboweldiseasesasystematicreviewandmetaanalysisofplacebocontrolledrandomizedclinicaltrials AT nedapouralimohamadi curcuminfortheclinicaltreatmentofinflammatoryboweldiseasesasystematicreviewandmetaanalysisofplacebocontrolledrandomizedclinicaltrials AT roghayehzare curcuminfortheclinicaltreatmentofinflammatoryboweldiseasesasystematicreviewandmetaanalysisofplacebocontrolledrandomizedclinicaltrials AT thomasrampp curcuminfortheclinicaltreatmentofinflammatoryboweldiseasesasystematicreviewandmetaanalysisofplacebocontrolledrandomizedclinicaltrials AT maryamshayesteh curcuminfortheclinicaltreatmentofinflammatoryboweldiseasesasystematicreviewandmetaanalysisofplacebocontrolledrandomizedclinicaltrials AT mehdipasalar curcuminfortheclinicaltreatmentofinflammatoryboweldiseasesasystematicreviewandmetaanalysisofplacebocontrolledrandomizedclinicaltrials |